Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Nebulisation with Dexmedetomidine with Lignocaine in awake nasal fibreoptic intubation: Patient will be nebulised with Dexmedetomidine 1 microgram/kg with 4ml of 4% Lignocaine
Interve
Sponsors
Dr Asmita Gupta
Eligibility
Inclusion criteria
Inclusion criteria: Patients giving written consent Patients of either sex Patients belonging to ASA grade I and II Patients with anticipated difficult intubation
Exclusion criteria
Exclusion criteria: Patient refusal. Patient with pregnancy, known alcoholic or drug abuser, or on chronic opioid therapy. Patient belonging to ASA grade IiII and above. Patients having hypersensitive reaction to drugs involved in the study. Patients with bradycardia, any atrioventricular block, heart failure, having significant neurological, hepatic,renal, and pulmonary disease. Patients undergoing emergency surgeries. Patients with psychiatric illness. Contraindication for nasal intubation like thrombocytopenia or coagulopathies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine better nebulising agent to blunt airway reflexes during awake fibreoptic nasal intubationTimepoint: 3 minutes | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine which interventional drug will ensure: Stable hemodynamics without respiratory depression during awake fibreoptic intubation Adequate patient cooperation Smooth intubating conditions (incidence of cough reflex, laryngospasm, gag reflex.Timepoint: 5 minutes | — |
Countries
India
Contacts
Public ContactDr Ravi Prakash
King George medical university
Outcome results
None listed